XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 4, 2020

Study Completion Date

May 4, 2020

Conditions
Opioid Dependence
Interventions
DRUG

Buprenorphine Extended Release

XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.

DRUG

Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)

SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.

Trial Locations (1)

10016

Bellevue Hospital Center, New York

All Listed Sponsors
collaborator

New York City Health and Hospitals Corporation

OTHER

lead

NYU Langone Health

OTHER

NCT03604159 - XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept | Biotech Hunter | Biotech Hunter